| Literature DB >> 35625586 |
Antony Hoarau1, Myriam Polette1, Christelle Coraux1.
Abstract
Hyaluronic acid (HA) is a major component of the extracellular matrix. It is synthesized by hyaluronan synthases (HAS) into high-molecular-weight chains (HMW-HA) that exhibit anti-inflammatory and immunomodulatory functions. In damaged, infected, and/or inflamed tissues, HMW-HA are degraded by hyaluronidases (HYAL) or reactive oxygen species (ROS) to give rise to low-molecular-weight HAs (LMW-HAs) that are potent pro-inflammatory molecules. Therefore, the size of HA regulates the balance of anti- or pro-inflammatory functions. The activities of HA depend also on its interactions with hyaladherins. HA synthesis, degradation, and activities through HA/receptors interactions define the hyaluronasome. In this review, a short overview of the role of high and low-molecular-weight HA polymers in the lungs is provided. The involvement of LMW-HA in pulmonary innate immunity via the activation of neutrophils, macrophages, dendritic cells, and epithelial cells is described to highlight LMW-HA as a therapeutic target in inflammatory respiratory diseases. Finally, the possibilities to counter LMW-HA's deleterious effects in the lungs are discussed.Entities:
Keywords: hyaluronic acid; inflammation; innate immunity; lung
Mesh:
Substances:
Year: 2022 PMID: 35625586 PMCID: PMC9138743 DOI: 10.3390/biom12050658
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Catabolism and recycling of HA. In a physiological context, native HA (>1000 kDa) is mainly recycled by HYAL1 and HYAL3. Its intracellular degradation continues within lysosomal vesicles to reach a 200 Da size. HAS1 mainly performs the neo-synthesis of HMW-HA. In a pathological/inflammatory context, HMW-HAs are fragmented by ROS and HYAL (mainly HYAL2) to form LMW-HAs with a size between 10 and 250 kDa, then degraded into 200 Da-sized fragments in lysosomes. The neo-synthesis of LMW-HA (10–250 kDa) occurs through HAS3. Created with BioRender.com.
LMW-HAs influence inflammatory marker expression.
| Target Cell | LMW-HA (kDa) | Receptor | Pathways | Inflammatory Effector | References |
|---|---|---|---|---|---|
| Neutrophils | |||||
| 100–200 | Not determined | Not determined | NE | [ | |
| 200 | Not determined | PI3K/Akt1 | IL-6 | [ | |
| 200 | Not determined | PI3K/Akt1 | KC | [ | |
| 200 | Not determined | PI3K/Akt1 | MMP-9 | [ | |
| 200 | Not determined | PI3K/Akt1 | MPO | [ | |
| 200 | Not determined | PI3K/Akt1 | Mcl-1 | [ | |
| Macrophages | |||||
| 200 | TLR2 | NF-κB | MIP-1α/β | [ | |
| 80 | TLR2 and TLR4 | Not determined | IL-8 | [ | |
| 100–150 | TLR2 and TLR4 | NF-κB | CXCL2 | [ | |
| 5 | TLR2 and TLR4 | Not determined | TNF-α | [ | |
| 5–200 | Not determined | NF-κB | NO | [ | |
| Not determined | TLR2 and TLR4 | Not determined | IL-1β | [ | |
| 60-200 | Not determined | NF-κB | MMP-9 | [ | |
| Not determined | Not determined | Not determined | PAI-1 | [ | |
| Not determined | Not determined | Not determined | uPA | [ | |
| 80 | TLR4 | NF-κB | IFN-β | [ | |
| 100–150 | CD44-TLR4 | Not determined | IL-6 | [ | |
| 100–150 | CD44-TLR4 | ERK1/2 and p38MAPK | MCP-1 | [ | |
| 200 | TLR4 | IRF3 | IFN-β | [ | |
| 200 | cPLA2α Phosphorylation | ERK1/2, p38MAPK and JNK | COX2 | [ | |
| 200 | cPLA2α Phosphorylation | ERK1/2, p38MAPK and JNK | PGE2 | [ | |
| 200 | Not determined | NF-κB | iNOS | [ | |
| 200 | Not determined | Not determined | MMP-12 | [ | |
| 280 | CD44 | Not determined | IL-12 | [ | |
| Dendritic Cells | |||||
| 80–200 | TLR4 | Not determined | IL-12 | [ | |
| 80–200 | TLR4 | Not determined | TNF-α | [ | |
| 80–200 | TLR4 | Not determined | IL-1β | [ | |
| Lung Epithelial Cells | |||||
| Not determined | TLR4 | Not determined | IL-6 | [ | |
| Not determined | CD44/TLR4/MD2/ MyD88 | NF-κB | MIP-2 | [ | |
| Not determined | CD44/TLR4/MD2/ Ras | NF-κB | MMP-13 | [ | |
| Not determined | CD44/TLR4/MD2/ Ras | NF-κB | TGF-β2 | [ | |
| 200 | Not determined | ERK1/2, AP-1, NF-κB and JNK | IL-8 | [ | |
| 200 | Not determined | NF-κB | IP-10 | [ |
Figure 2LMW-HA and lung hyaluronasome. LMW-HAs promote lung hyper-inflammation through hyaladherin interactions (CD44, TLR2, and TLR4, RHAMM, and HARE/Stab-2) and increase the secretion of cytokines (TNF-α, IFN-β, and IL-6), chemokines (IL-8), ROS, or enzymes (NE and MMPs). LMW-HAs also have beneficial impacts on the airway epithelium by increasing the CBF and by modulating intercellular junction protein expression. The dual functions of LMW-HAs maintain/amplify the lung inflammation while participating in the protection of the epithelium. Created with BioRender.com.